Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-06-12

AUTHORS

Joan Carles, Isabel Chirivella, Miguel Ángel Climent, Enrique Gallardo, Arancha González del Alba, José Pablo Maroto, Begoña Mellado, Francisco Xavier García del Muro

ABSTRACT

The approval and use of molecular targeted agents for the first-line treatment of metastatic renal cell carcinoma (mRCC) has substantially improved the clinical outcome of patients. Although eventually all patients progress, hopes have been renewed with the approval of everolimus for patients who progress on or after treatment with tyrosine kinase inhibitors. In order to improve the prognosis for these patients, it is imperative to understand the reasons why patients with mRCC fail on first-line treatment. Currently, progression is assessed on the basis of the Response Evaluation Criteria in Solid Tumors, but it is known that targeted agents tend to cause disease stabilization rather than a significant decrease in tumor mass. Therefore, it may be time to evaluate the need to incorporate additional diagnostic methods in the assessment of disease response. Equally important is the study of the factors that determine the success or failure of second-line therapy in order to increase the chances of delivering the most effective and personalized therapy possible. In this article, we review the evidence related to the evaluation of patients with mRCC who fail on first-line treatment with targeted agents, including the systems to assess response and progression, the prognostic factors, the prognostic models that have been created based on these factors, and what is known about predictive biomarkers of disease outcome. More... »

PAGES

3-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0

DOI

http://dx.doi.org/10.1007/s10555-012-9353-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013240949

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22689342


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Service, Hospital Universitari Vall d\u2019Hebron, Passeig de la Vall d\u2019Hebron, 119-129, 08035, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Medical Oncology Service, Hospital Universitari Vall d\u2019Hebron, Passeig de la Vall d\u2019Hebron, 119-129, 08035, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carles", 
        "givenName": "Joan", 
        "id": "sg:person.0633222263.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633222263.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411308.f", 
          "name": [
            "Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chirivella", 
        "givenName": "Isabel", 
        "id": "sg:person.01322202424.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322202424.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda, Valencia, Spain", 
          "id": "http://www.grid.ac/institutes/grid.418082.7", 
          "name": [
            "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda, Valencia, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Climent", 
        "givenName": "Miguel \u00c1ngel", 
        "id": "sg:person.01305201047.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305201047.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, l\u2019Hospital de Sabadell, Sabadell, Spain", 
          "id": "http://www.grid.ac/institutes/grid.428313.f", 
          "name": [
            "Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, l\u2019Hospital de Sabadell, Sabadell, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallardo", 
        "givenName": "Enrique", 
        "id": "sg:person.01264637747.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264637747.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitari Son Dureta, Palma de Mallorca, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411161.2", 
          "name": [
            "Hospital Universitari Son Dureta, Palma de Mallorca, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonz\u00e1lez del Alba", 
        "givenName": "Arancha", 
        "id": "sg:person.01221412261.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221412261.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.413396.a", 
          "name": [
            "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maroto", 
        "givenName": "Jos\u00e9 Pablo", 
        "id": "sg:person.01301016555.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301016555.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Clinic de Barcelona, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/grid.410458.c", 
          "name": [
            "Hospital Clinic de Barcelona, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mellado", 
        "givenName": "Bego\u00f1a", 
        "id": "sg:person.01234274675.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234274675.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Catal\u00e0 d\u2019Oncolog\u00eda, Hospital Duran i Reynals, l\u2019Hospitalet de Llobregat, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Institut Catal\u00e0 d\u2019Oncolog\u00eda, Hospital Duran i Reynals, l\u2019Hospitalet de Llobregat, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garc\u00eda del Muro", 
        "givenName": "Francisco Xavier", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11523-010-0146-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030648477", 
          "https://doi.org/10.1007/s11523-010-0146-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-0018-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032981147", 
          "https://doi.org/10.1007/s10549-008-0018-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-12", 
    "datePublishedReg": "2012-06-12", 
    "description": "The approval and use of molecular targeted agents for the first-line treatment of metastatic renal cell carcinoma (mRCC) has substantially improved the clinical outcome of patients. Although eventually all patients progress, hopes have been renewed with the approval of everolimus for patients who progress on or after treatment with tyrosine kinase inhibitors. In order to improve the prognosis for these patients, it is imperative to understand the reasons why patients with mRCC fail on first-line treatment. Currently, progression is assessed on the basis of the Response Evaluation Criteria in Solid Tumors, but it is known that targeted agents tend to cause disease stabilization rather than a significant decrease in tumor mass. Therefore, it may be time to evaluate the need to incorporate additional diagnostic methods in the assessment of disease response. Equally important is the study of the factors that determine the success or failure of second-line therapy in order to increase the chances of delivering the most effective and personalized therapy possible. In this article, we review the evidence related to the evaluation of patients with mRCC who fail on first-line treatment with targeted agents, including the systems to assess response and progression, the prognostic factors, the prognostic models that have been created based on these factors, and what is known about predictive biomarkers of disease outcome.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10555-012-9353-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096239", 
        "issn": [
          "0167-7659", 
          "1573-7233"
        ], 
        "name": "Cancer and Metastasis Reviews", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "metastatic renal cell carcinoma", 
      "first-line treatment", 
      "evaluation of patients", 
      "renal cell carcinoma", 
      "cell carcinoma", 
      "second-line therapy", 
      "approval of everolimus", 
      "Response Evaluation Criteria", 
      "tyrosine kinase inhibitors", 
      "additional diagnostic methods", 
      "disease stabilization", 
      "prognostic factors", 
      "clinical outcomes", 
      "targeted agents", 
      "predictive biomarkers", 
      "disease outcome", 
      "tumor mass", 
      "patients", 
      "solid tumors", 
      "prognostic model", 
      "personalized therapy", 
      "significant decrease", 
      "disease response", 
      "kinase inhibitors", 
      "treatment", 
      "carcinoma", 
      "diagnostic methods", 
      "therapy", 
      "progression", 
      "outcomes", 
      "approval", 
      "agents", 
      "failure", 
      "everolimus", 
      "prognosis", 
      "tumors", 
      "factors", 
      "response", 
      "biomarkers", 
      "evaluation", 
      "inhibitors", 
      "evaluation criteria", 
      "assessment", 
      "evidence", 
      "decrease", 
      "criteria", 
      "study", 
      "chance", 
      "use", 
      "hope", 
      "need", 
      "mass", 
      "reasons", 
      "success", 
      "time", 
      "stabilization", 
      "basis", 
      "article", 
      "method", 
      "model", 
      "order", 
      "system"
    ], 
    "name": "Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment", 
    "pagination": "3-9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013240949"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10555-012-9353-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22689342"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10555-012-9353-0", 
      "https://app.dimensions.ai/details/publication/pub.1013240949"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_570.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10555-012-9353-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10555-012-9353-0'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      22 PREDICATES      95 URIs      85 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10555-012-9353-0 schema:about N0fd6eadc2f04424b9b080e21e6edc306
2 N7466e5f3c0e9472795ea1d83a80862c3
3 N9a018327465b478a8d1de7ee5fdd02f2
4 Nb8dbd864c3984da5a13b14e27037116e
5 Nca5a61f4f0354cd2a42a5712fb396bd2
6 Ne5c113f79e9e4ddcaeb70efaa16f238e
7 anzsrc-for:11
8 anzsrc-for:1103
9 schema:author N5a3510f9521c463f8c8abdd00ff31e78
10 schema:citation sg:pub.10.1007/s10549-008-0018-1
11 sg:pub.10.1007/s11523-010-0146-5
12 schema:datePublished 2012-06-12
13 schema:datePublishedReg 2012-06-12
14 schema:description The approval and use of molecular targeted agents for the first-line treatment of metastatic renal cell carcinoma (mRCC) has substantially improved the clinical outcome of patients. Although eventually all patients progress, hopes have been renewed with the approval of everolimus for patients who progress on or after treatment with tyrosine kinase inhibitors. In order to improve the prognosis for these patients, it is imperative to understand the reasons why patients with mRCC fail on first-line treatment. Currently, progression is assessed on the basis of the Response Evaluation Criteria in Solid Tumors, but it is known that targeted agents tend to cause disease stabilization rather than a significant decrease in tumor mass. Therefore, it may be time to evaluate the need to incorporate additional diagnostic methods in the assessment of disease response. Equally important is the study of the factors that determine the success or failure of second-line therapy in order to increase the chances of delivering the most effective and personalized therapy possible. In this article, we review the evidence related to the evaluation of patients with mRCC who fail on first-line treatment with targeted agents, including the systems to assess response and progression, the prognostic factors, the prognostic models that have been created based on these factors, and what is known about predictive biomarkers of disease outcome.
15 schema:genre article
16 schema:inLanguage en
17 schema:isAccessibleForFree false
18 schema:isPartOf N82947823023f47cbaad254c5df13c486
19 Nef3604cb2a7e4b3b8d74c9d29787c208
20 sg:journal.1096239
21 schema:keywords Response Evaluation Criteria
22 additional diagnostic methods
23 agents
24 approval
25 approval of everolimus
26 article
27 assessment
28 basis
29 biomarkers
30 carcinoma
31 cell carcinoma
32 chance
33 clinical outcomes
34 criteria
35 decrease
36 diagnostic methods
37 disease outcome
38 disease response
39 disease stabilization
40 evaluation
41 evaluation criteria
42 evaluation of patients
43 everolimus
44 evidence
45 factors
46 failure
47 first-line treatment
48 hope
49 inhibitors
50 kinase inhibitors
51 mass
52 metastatic renal cell carcinoma
53 method
54 model
55 need
56 order
57 outcomes
58 patients
59 personalized therapy
60 predictive biomarkers
61 prognosis
62 prognostic factors
63 prognostic model
64 progression
65 reasons
66 renal cell carcinoma
67 response
68 second-line therapy
69 significant decrease
70 solid tumors
71 stabilization
72 study
73 success
74 system
75 targeted agents
76 therapy
77 time
78 treatment
79 tumor mass
80 tumors
81 tyrosine kinase inhibitors
82 use
83 schema:name Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
84 schema:pagination 3-9
85 schema:productId N825535f4727549e78d0af97f658580ae
86 Nc6e0311f8c024615bed16ea31a516daa
87 Ne9e0918313ec45ef8affbd5d3faa3f66
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013240949
89 https://doi.org/10.1007/s10555-012-9353-0
90 schema:sdDatePublished 2022-01-01T18:27
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher Nca0a992c4846447eb219a778b473f11d
93 schema:url https://doi.org/10.1007/s10555-012-9353-0
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N09e33203b368413088d088c8323058f9 rdf:first sg:person.01322202424.66
98 rdf:rest N6285ba2b4c324911a929b8d359bb72c6
99 N0fd6eadc2f04424b9b080e21e6edc306 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Neoplasm Metastasis
101 rdf:type schema:DefinedTerm
102 N1903efe7b2194746a4c5b060ade60657 rdf:first sg:person.01234274675.99
103 rdf:rest N729e09ddedb246eb90cb0e363a58a476
104 N21d5b195720a4147b1fdee5a07497606 rdf:first sg:person.01221412261.54
105 rdf:rest Ndda9ed421e3f416f891fdf1b9e7aa83d
106 N52ca6fd6e9f744deb468b890a5988aac rdf:first sg:person.01264637747.43
107 rdf:rest N21d5b195720a4147b1fdee5a07497606
108 N5a3510f9521c463f8c8abdd00ff31e78 rdf:first sg:person.0633222263.47
109 rdf:rest N09e33203b368413088d088c8323058f9
110 N6285ba2b4c324911a929b8d359bb72c6 rdf:first sg:person.01305201047.47
111 rdf:rest N52ca6fd6e9f744deb468b890a5988aac
112 N729e09ddedb246eb90cb0e363a58a476 rdf:first N7788d68191f34d6ebdb8cf9e2d37def6
113 rdf:rest rdf:nil
114 N7466e5f3c0e9472795ea1d83a80862c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Prognosis
116 rdf:type schema:DefinedTerm
117 N7788d68191f34d6ebdb8cf9e2d37def6 schema:affiliation grid-institutes:None
118 schema:familyName García del Muro
119 schema:givenName Francisco Xavier
120 rdf:type schema:Person
121 N825535f4727549e78d0af97f658580ae schema:name pubmed_id
122 schema:value 22689342
123 rdf:type schema:PropertyValue
124 N82947823023f47cbaad254c5df13c486 schema:issueNumber Suppl 1
125 rdf:type schema:PublicationIssue
126 N9a018327465b478a8d1de7ee5fdd02f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Kidney Neoplasms
128 rdf:type schema:DefinedTerm
129 Nb8dbd864c3984da5a13b14e27037116e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Humans
131 rdf:type schema:DefinedTerm
132 Nc6e0311f8c024615bed16ea31a516daa schema:name doi
133 schema:value 10.1007/s10555-012-9353-0
134 rdf:type schema:PropertyValue
135 Nca0a992c4846447eb219a778b473f11d schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 Nca5a61f4f0354cd2a42a5712fb396bd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Carcinoma, Renal Cell
139 rdf:type schema:DefinedTerm
140 Ndda9ed421e3f416f891fdf1b9e7aa83d rdf:first sg:person.01301016555.42
141 rdf:rest N1903efe7b2194746a4c5b060ade60657
142 Ne5c113f79e9e4ddcaeb70efaa16f238e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Treatment Outcome
144 rdf:type schema:DefinedTerm
145 Ne9e0918313ec45ef8affbd5d3faa3f66 schema:name dimensions_id
146 schema:value pub.1013240949
147 rdf:type schema:PropertyValue
148 Nef3604cb2a7e4b3b8d74c9d29787c208 schema:volumeNumber 31
149 rdf:type schema:PublicationVolume
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1096239 schema:issn 0167-7659
157 1573-7233
158 schema:name Cancer and Metastasis Reviews
159 schema:publisher Springer Nature
160 rdf:type schema:Periodical
161 sg:person.01221412261.54 schema:affiliation grid-institutes:grid.411161.2
162 schema:familyName González del Alba
163 schema:givenName Arancha
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221412261.54
165 rdf:type schema:Person
166 sg:person.01234274675.99 schema:affiliation grid-institutes:grid.410458.c
167 schema:familyName Mellado
168 schema:givenName Begoña
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234274675.99
170 rdf:type schema:Person
171 sg:person.01264637747.43 schema:affiliation grid-institutes:grid.428313.f
172 schema:familyName Gallardo
173 schema:givenName Enrique
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264637747.43
175 rdf:type schema:Person
176 sg:person.01301016555.42 schema:affiliation grid-institutes:grid.413396.a
177 schema:familyName Maroto
178 schema:givenName José Pablo
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301016555.42
180 rdf:type schema:Person
181 sg:person.01305201047.47 schema:affiliation grid-institutes:grid.418082.7
182 schema:familyName Climent
183 schema:givenName Miguel Ángel
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305201047.47
185 rdf:type schema:Person
186 sg:person.01322202424.66 schema:affiliation grid-institutes:grid.411308.f
187 schema:familyName Chirivella
188 schema:givenName Isabel
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322202424.66
190 rdf:type schema:Person
191 sg:person.0633222263.47 schema:affiliation grid-institutes:grid.411083.f
192 schema:familyName Carles
193 schema:givenName Joan
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633222263.47
195 rdf:type schema:Person
196 sg:pub.10.1007/s10549-008-0018-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032981147
197 https://doi.org/10.1007/s10549-008-0018-1
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s11523-010-0146-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030648477
200 https://doi.org/10.1007/s11523-010-0146-5
201 rdf:type schema:CreativeWork
202 grid-institutes:None schema:alternateName Institut Català d’Oncología, Hospital Duran i Reynals, l’Hospitalet de Llobregat, Barcelona, Spain
203 schema:name Institut Català d’Oncología, Hospital Duran i Reynals, l’Hospitalet de Llobregat, Barcelona, Spain
204 rdf:type schema:Organization
205 grid-institutes:grid.410458.c schema:alternateName Hospital Clinic de Barcelona, Barcelona, Spain
206 schema:name Hospital Clinic de Barcelona, Barcelona, Spain
207 rdf:type schema:Organization
208 grid-institutes:grid.411083.f schema:alternateName Medical Oncology Service, Hospital Universitari Vall d’Hebron, Passeig de la Vall d’Hebron, 119-129, 08035, Barcelona, Spain
209 schema:name Medical Oncology Service, Hospital Universitari Vall d’Hebron, Passeig de la Vall d’Hebron, 119-129, 08035, Barcelona, Spain
210 rdf:type schema:Organization
211 grid-institutes:grid.411161.2 schema:alternateName Hospital Universitari Son Dureta, Palma de Mallorca, Spain
212 schema:name Hospital Universitari Son Dureta, Palma de Mallorca, Spain
213 rdf:type schema:Organization
214 grid-institutes:grid.411308.f schema:alternateName Hospital Clínico Universitario de Valencia, Valencia, Spain
215 schema:name Hospital Clínico Universitario de Valencia, Valencia, Spain
216 rdf:type schema:Organization
217 grid-institutes:grid.413396.a schema:alternateName Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
218 schema:name Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
219 rdf:type schema:Organization
220 grid-institutes:grid.418082.7 schema:alternateName Fundación Instituto Valenciano de Oncología, Valencia, Spain
221 schema:name Fundación Instituto Valenciano de Oncología, Valencia, Spain
222 rdf:type schema:Organization
223 grid-institutes:grid.428313.f schema:alternateName Corporació Sanitària Parc Taulí, l’Hospital de Sabadell, Sabadell, Spain
224 schema:name Corporació Sanitària Parc Taulí, l’Hospital de Sabadell, Sabadell, Spain
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...